OptiNose, Inc. (OPTN)
9.60
-0.11 (-1.13%)
Inactive · Last trade price on May 20, 2025

Company Description

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists.

It offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase III clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.

The company was founded in 2000 and is headquartered in Yardley, Pennsylvania. As of May 21, 2025, OptiNose, Inc. operates as a subsidiary of Paratek Pharmaceuticals, Inc.

OptiNose, Inc.
OptiNose logo
CountryUnited States
Founded2010
IPO DateOct 13, 2017
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees128
CEORamy Mahmoud

Contact Details

Address:
777 Township Line Road, Suite 300
Yardley, Pennsylvania 19067
United States
Phone267 364 3500
Websiteoptinose.com

Stock Details

Ticker SymbolOPTN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001494650
CUSIP Number68404V100
ISIN NumberUS68404V1008
Employer ID42-1771610
SIC Code2834

Key Executives

NamePosition
Dr. Ramy A. Mahmoud M.D., M.P.H.Chief Executive Officer and Director
Michael F. Marino Esq.Chief Legal Officer and Corporate Secretary
Paul SpenceChief Commercial Officer
P. Terence KohlerChief Financial Officer
Anthony J. KrickVice President of Finance and Chief Accounting Officer
Jonathan NeelyVice President of Investor Relations and Business Development
Karen E. BrophyChief Human Resources Officer and Vice President of Human Resources

Latest SEC Filings

DateTypeTitle
May 21, 2025EFFECTNotice of Effectiveness
May 21, 2025EFFECTNotice of Effectiveness
May 21, 2025EFFECTNotice of Effectiveness
May 21, 2025EFFECTNotice of Effectiveness
May 21, 2025EFFECTNotice of Effectiveness
May 21, 2025EFFECTNotice of Effectiveness
May 21, 2025EFFECTNotice of Effectiveness
May 21, 202525-NSEFiling
May 21, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
May 21, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments